Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society

Eledon Pharmaceuticals presented updated long-term data from its Phase 2 BESTOW clinical program for tegoprubart at the International Congress of The Transplantation Society. The data showed that tegoprubart-treated patients had a statistically significant advantage in kidney function, with a mean eGFR of 71 mL/min/1.73 m² compared to 58 mL/min/1.73 m² for tacrolimus at 24 months. Additionally, no rejections occurred in the tegoprubart group beyond six months post-transplant, while seven rejections were reported in the tacrolimus group. Eledon has received FDA Fast Track designation for tegoprubart and plans to initiate a Phase 3 LEGACY study in Q4 2026, aiming to enroll approximately 600 patients.